Oncolytics Biotech, Inc. (ONCY) is around the top of the Biotechnology industry according to InvestorsObserver. ONCY received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. Oncolytics Biotech, Inc. also achieved a score of 99 in the Biotechnology industry, putting it above 99 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 85 means the stock is more attractive than 85 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Oncolytics Biotech, Inc. (ONCY) stock is down -2.44% while the S&P 500 has risen 5.92% as of 2:02 PM on Monday, Apr 6. ONCY is down -$0.04 from the previous closing price of $1.45 on volume of 194,581 shares. Over the past year the S&P 500 is down -8.97% while ONCY is down -24.19%. ONCY lost -$1.05 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Oncolytics Biotech, Inc. click here.

Continue reading here:
Industry Breakdown: Where Does Oncolytics Biotech, Inc. (ONCY) Stock Fall in the Biotechnology Field? - InvestorsObserver